title: Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.
abstract: Stent thrombosis remains a significant pitfall of percutaneous coronary intervention (PCI). A recent trial observed that an adjusted loading dose (LD) of clopidogrel according to platelet monitoring decreases the rate of major adverse cardiovascular events after PCI. We investigated if such a strategy of a tailored clopidogrel LD according to platelet reactivity monitoring could decrease the rate of stent thrombosis. This multicenter prospective randomized study included 429 patients with a low clopidogrel response after a 600-mg LD undergoing PCI. Patients were randomized to a control group (n = 214) and to a vasodilator-stimulated phosphoprotein (VASP)-guided group (n = 215). In the VASP-guided group, patients received up to 3 additional 600-mg LDs of clopidogrel to obtain a VASP index <50% before PCI. The primary end point was the rate of stent thrombosis at 1 month. Secondary end points were rates of major adverse cardiovascular events and bleeding. Patients in the 2 groups had a high body mass index and were often diabetic (control vs VASP-guided group 28 +/- 5.1 vs 27.9 +/- 4.7 kg/m(2), p = 0.8, and 39% vs 33%, p = 0.2, respectively). PCI was performed in most patients for acute coronary syndrome in the 2 groups (52.3% vs 50.7%, p = 0.8). Despite a 2,400-mg LD of clopidogrel, 8% of patients in the VASP-guided group remained low responders. The rate of stent thrombosis was significantly lower in the VASP-guided group (0.5% vs 4.2%, p <0.01). The rate of major adverse cardiovascular events was also higher in the control group (8.9% vs 0.5%, p <0.001). There was no difference in the rate of bleeding (2.8% vs 3.7%, p = 0.8). In conclusion, a tailored clopidogrel LD according to platelet reactivity monitoring decreases the rate of early stent thrombosis after PCI without increasing bleeding.
authors.affiliation: Département de cardiologie, Hôpital universitaire nord, Faculté de médecine, France. laurentbonello@yahoo.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Bonello
authors.forename: Laurence
authors.initials: L
authors.lastname: Camoin-Jau
authors.forename: Sébastien
authors.initials: S
authors.lastname: Armero
authors.forename: Olivier
authors.initials: O
authors.lastname: Com
authors.forename: Stéphane
authors.initials: S
authors.lastname: Arques
authors.forename: Caroline
authors.initials: C
authors.lastname: Burignat-Bonello
authors.forename: Marie-Paule
authors.initials: MP
authors.lastname: Giacomoni
authors.forename: Roland
authors.initials: R
authors.lastname: Bonello
authors.forename: Frédéric
authors.initials: F
authors.lastname: Collet
authors.forename: Philippe
authors.initials: P
authors.lastname: Rossi
authors.forename: Paul
authors.initials: P
authors.lastname: Barragan
authors.forename: Françoise
authors.initials: F
authors.lastname: Dignat-George
authors.forename: Franck
authors.initials: F
authors.lastname: Paganelli
mesh_terms: D000208:Acute Disease; D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000601:surgery*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D000077144:Clopidogrel; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000097:blood / Q000000981:diagnostic imaging / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000097:blood / Q000000981:diagnostic imaging / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D009204:Myocardial Revascularization / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011446:Prospective Studies; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine